$15.27
0.33% yesterday
Nasdaq, Sep 03, 10:00 pm CET
ISIN
US44842L1035
Symbol
HCM

Hutchison China MediTech Limited Sponsored ADR Stock price

$15.27
-2.01 11.63% 1M
-0.64 4.02% 6M
+0.86 5.97% YTD
-2.17 12.44% 1Y
+2.37 18.37% 3Y
-19.29 55.82% 5Y
+1.87 13.96% 10Y
+1.87 13.96% 20Y
Nasdaq, Closing price Wed, Sep 03 2025
-0.05 0.33%
ISIN
US44842L1035
Symbol
HCM
Industry

Key metrics

Basic
Market capitalization
$2.7b
Enterprise Value
$1.4b
Net debt
positive
Cash
$1.4b
Shares outstanding
872.1m
Valuation (TTM | estimate)
P/E
28.3 | 31.4
P/S
4.5 | 4.2
EV/Sales
2.4 | 2.2
EV/FCF
negative
P/B
2.2
Financial Health
Equity Ratio
-
Return on Equity
-
ROCE
-1.4%
ROIC
-5.8%
Debt/Equity
0.1
Financials (TTM | estimate)
Revenue
$602.2m | $647.4m
EBITDA
$-7.5m | $16.3m
EBIT
$-19.7m | $14.6m
Net Income
$466.9m | $424.6m
Free Cash Flow
$-59.7m
Growth (TTM | estimate)
Revenue
-1.4% | 2.7%
EBITDA
93.2% | 152.1%
EBIT
83.7% | 133.3%
Net Income
1,212.4% | 1,025.3%
Free Cash Flow
8.7%
Margin (TTM | estimate)
Gross
44.2%
EBITDA
-1.2% | 2.5%
EBIT
-3.3%
Net
77.5% | 65.6%
Free Cash Flow
-9.9%
More
EPS
$0.5
FCF per Share
$-0.1
Short interest
0.5%
Employees
-
Rev per Employee
-
Show more

Is Hutchison China MediTech Limited Sponsored ADR a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,003 stocks worldwide.

Hutchison China MediTech Limited Sponsored ADR Stock Analysis

Unlock Scores for Free

Analyst Opinions

27 Analysts have issued a Hutchison China MediTech Limited Sponsored ADR forecast:

24x Buy
89%
3x Hold
11%

Analyst Opinions

27 Analysts have issued a Hutchison China MediTech Limited Sponsored ADR forecast:

Buy
89%
Hold
11%

Financial data from Hutchison China MediTech Limited Sponsored ADR

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '25
+/-
%
602 602
1% 1%
100%
- Direct Costs 336 336
6% 6%
56%
266 266
4% 4%
44%
- Selling and Administrative Expenses 97 97
21% 21%
16%
- Research and Development Expense 189 189
25% 25%
31%
-7.49 -7.49
93% 93%
-1%
- Depreciation and Amortization 12 12
15% 15%
2%
EBIT (Operating Income) EBIT -20 -20
84% 84%
-3%
Net Profit 467 467
1,212% 1,212%
78%

In millions USD.

Don't miss a Thing! We will send you all news about Hutchison China MediTech Limited Sponsored ADR directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Hutchison China MediTech Limited Sponsored ADR Stock News

Neutral
GlobeNewsWire
10 days ago
HONG KONG and SHANGHAI and FLORHAM PARK, N.J, Aug. 25, 2025 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:​HCM; HKEX:​13) today announces that Dr Weiguo Su, an Executive Director of the Company, will take a leave of absence from his duties as Chief Executive Officer due to health reasons. In light of this, the Board of Directors has appointed Mr Johnny Cheng, an Executiv...
Neutral
GlobeNewsWire
15 days ago
HONG KONG and SHANGHAI and FLORHAM PARK, N.J., Aug. 20, 2025 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:​HCM; HKEX:​13) today announces the completion of patient enrollment of SANOVO, a China Phase III study of ORPATHYS® (savolitinib) and TAGRISSO® (osimertinib) as a first-line treatment in certain non-small cell lung cancer (“NSCLC”) patients whose tumors harbor epid...
Neutral
Seeking Alpha
27 days ago
HUTCHMED (China) Limited (NASDAQ:HCM ) Q2 2025 Earnings Conference Call August 7, 2025 8:00 AM ET Company Participants Chig Fung Cheng - CFO & Executive Director David Ng - Head of Investor Relations & Capital Strategies George Yuan - Corporate Participant Ming Shi - Executive VP, Head of R&D and Chief Medical Officer Wei-Guo Su - CEO, Chief Scientific Officer & Executive Director Conference Ca...
More Hutchison China MediTech Limited Sponsored ADR News

Company Profile

Hutchison China MediTech Ltd. is a holding company, which engages in the research and development, manufactures, and sells pharmaceuticals and health oriented consumer products. It operates through the Innovation Platform and Commercial Platform segments. The Innovation Platform segment relates to research and development of innovative therapeutics in oncology and autoimmune diseases. The Commercial Platform segment relates to prescription drugs which develops, manufacture, markets, and sale of prescription pharmaceuticals; and consumer health which comprised of development, manufacture, distribution, and marketing of over-the-counter pharmaceuticals, and consumer health products. The company was founded in June 2000 and is headquartered in Hong Kong.

Head office Cayman Islands
CEO Wei Su
Founded 2000
Website www.hutch-med.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today